Company intelligence / Profile preview

Sequoia Vaccines, Inc.

St. Louis, Missouri, United Statessequoiavaccines.com ↗

Ownership: Private
Employees: ~5
Development stage: Phase 1

Overview

Lead program SEQ-400 has completed Phase 1 trials and is currently in Phase 2 for recurrent UTIs. The company has received fast track designation from the FDA in December 2017 for this program. A Phase 2 Observational Lead-In human study is set to begin in 2025.

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccinesSmall molecules
Industry: Biotech

Drug pipeline

2 assets

SEQ-1274

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Sequoia Vaccines, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sequoia Vaccines, Inc..

Explore the full profile